Home > Cardiology > AHA 2020 > Heart Failure > IV iron reduces HF hospitalisation

IV iron reduces HF hospitalisation

Presented By
Prof. Piotr Ponikowski, Wroclaw Medical University, Poland
Conference
AHA 2020
Trial
AFFIRM-AHF

The results of the AFFIRM-AHF trial demonstrated that addressing iron deficiency in patients with heart failure (HF) can decrease the risk of subsequent hospitalisations following an acute HF event. Although the study narrowly missed its primary endpoint, it did demonstrate that intravenous (IV) iron resulted in a significant 26% drop in HF hospitalisations [1].

Prof. Piotr Ponikowski (Wroclaw Medical University, Poland) presented the results of the AFFIRM-AHF trial (NCT02937454), which were simultaneously published in The Lancet [2]. AFFIRM-AHF was a multicentre study in 1,132 patients hospitalised for acute HF. The average age was 71 years, 56% were male, and 41% had diabetes. Average LVEF was 33%. All participants had serum ferritin <100 ng/mL (or 100–299 ng/mL and a transferrin saturation <20%) and a left ventricular ejection fraction (LVEF) <...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on